ArticleFrontiers in psychiatry2024
Enhanced computerized cognitive remediation therapy improved cognitive function, negative symptoms, and GDNF in male long-term inpatients with schizophrenia.
Article in Frontiers in psychiatry, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Digital and Immersive Technologies for Rehabilitation in Complex Psychosis: State of the Art and Future Directions.Medicina (Kaunas, Lithuania) · 2026Review
- Article
- Cognitive Remediation as a Tool for Enhancing Treatment Dimensions of Schizophrenic Symptomatology: A Systematic Review of Randomized Controlled Trials.Brain sciences · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Negative and cognitive symptoms present significant challenges in patients with schizophrenia, and cognitive remediation is a promising approach to alleviate these symptoms. This study aimed to explore the efficacy of computerized cognitive remediation therapy (CCRT) on psychiatric symptoms, cognitive deficits, and serum levels of brain-derived neurotrophic factor (BDNF) and glial cell line-derived neurotrophic factor (GDNF) in patients with schizophrenia. Materials and methods: Forty male long-term institutionalized inpatients with schizophrenia were assigned to either a CCRT group (n = 20) or a control group (n = 20). The CCRT intervention consisted of 40 individual 40-min sessions over 8 weeks, conducted five times a week. Psychiatric symptoms, cognition, and serum levels of BDNF and GDNF were assessed at baseline, 4 weeks, and 8 weeks. Results: Compared to the control group, the CCRT group exhibited decreased total Positive and Negative Syndrome Scale and negative subscale scores, as well as increased Montreal Cognitive Assessment and Repeatable Battery for the Assessment of Neuropsychological Status scores. Moreover, improvements in list recall were associated with reduced negative symptoms. Additionally, CCRT ameliorated the decrease in serum GDNF levels in patients with schizophrenia. Conclusion: The effectiveness of CCRT in alleviating negative symptoms was associated with improvements in list recall, and GDNF may play a role in the observed effects of CCRT in patients with schizophrenia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.